Projects per year
Fingerprint
Dive into the research topics where Jens Tijtgat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
Research output
-
Neurocognitive Functioning in Metastatic Cancer Survivors Treated With Immune Checkpoint Blockade: First Results of A Single Center Cohort Study
Vanlaer, N., Kyndt, D., Van Eycken, S., Tijtgat, J., Kessels, J., Dirven, I., Vounckx, M., Neyns, B. & Rogiers, A., 31 Jan 2023.Research output: Unpublished contribution to conference › Poster
-
790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab
Tijtgat, J., Schwarze, J. K., Vander Mijnsbrugge, A-S., Raeymaeckers, S., Van Riet, I., Geeraerts, X., Stevens, L., Tuyaerts, S. & Neyns, B., 7 Nov 2022, In: Journal for immunotherapy of cancer. 10, Suppl 2Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 Jun 2022, In: Melanoma Research. 32, 3, p. 183-191 9 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Seynaeve, L., Vanbinst, A-M., Everaert, H., Michotte, A., Bruneau, M., Van Riet, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 1 Jun 2022, In: Journal of Clinical Oncology. 40, 16, 2033.Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Vanbinst, A., Everaert, H., Seynaeve, L., Michotte, A., Bruneau, M., VAN RIET, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 3 Jun 2022.Research output: Unpublished contribution to conference › Poster
Prizes
-
Young Investigator Award
Tijtgat, Jens (Recipient), 11 Sep 2022
Prize: Prize (including medals and awards)
Activities
-
Novartis (Belgium) (External organisation)
Jens Tijtgat (Chair)
2022 → 2023Activity: Membership › Work on advisory panel to industry or government or non-government organisation
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase Ib/II clinical trial on intratumoral autologous myeloid dendritic cell therapy in combination with AS01B adjuvant and immune-checkpoint blockade
Jens Tijtgat (Speaker)
19 May 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
Press/Media
-
Onderzoekers van het UZ Brussel ontdekken een nieuwe efficiënte behandeling voor resistente melanoom huidkanker
24/11/22
1 Media contribution
Press/Media: Research
Thesis
-
IMMUNOGENIC CELL DEATH IN ONCOLYTIC VIROTHERAPY: T-VEC in the treatment of cutaneous melanoma
Author: Tijtgat, J., 2019Student thesis: Master's Thesis